Was Buffett Wrong About This Blue Chip?
Our health care roundtable gathers The Motley Fool's top health care analysts to discuss the sector's biggest stories in a free flowing and highly opinionated format.
In this portion of the video, our guys discuss Warren Buffett's latest portfolio moves in the health care industry. They also continue debate regarding the merits of spinning off businesses, such as Abbott Labs' spinoff of Abbvie as of the first of next year. They take a look at Merck and Johnson & Johnson , two companies sticking by the conglomerate model and retaining all of their businesses, and they explore if they think it's the right approach.
In the world of health care, companies simply don't come any bigger than Johnson & Johnson. Many own the stock, but few understand its story. Offering everything from baby powder to biologics, critics think the company has spread itself too thin, becoming nothing more than a bloated corporate whale. Is this true, or is J&J a well-diversified giant that's perfect for your portfolio? Make sure you understand the full story behind the stock, along with its key opportunities and risks, by checking out our brand new premium report on Johnson & Johnson. To claim your copy simply click here now for instant access.
The article Was Buffett Wrong About This Blue Chip? originally appeared on Fool.com.
Brenton Flynn has no positions in the stocks mentioned above. David Williamson owns shares of Berkshire Hathaway. The Motley Fool owns shares of Berkshire Hathaway, International Business Machines, and Johnson & Johnson. Motley Fool newsletter services recommend Berkshire Hathaway, International Business Machines, and Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.
